[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3402515T3 - Forbedrede fremgangsmåder til monitorering af et individs immunstatus - Google Patents

Forbedrede fremgangsmåder til monitorering af et individs immunstatus Download PDF

Info

Publication number
DK3402515T3
DK3402515T3 DK17738918.6T DK17738918T DK3402515T3 DK 3402515 T3 DK3402515 T3 DK 3402515T3 DK 17738918 T DK17738918 T DK 17738918T DK 3402515 T3 DK3402515 T3 DK 3402515T3
Authority
DK
Denmark
Prior art keywords
monitoring
individual
immune status
improved procedures
procedures
Prior art date
Application number
DK17738918.6T
Other languages
English (en)
Inventor
James Richard Berenson
Original Assignee
Oncotracker Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotracker Inc filed Critical Oncotracker Inc
Application granted granted Critical
Publication of DK3402515T3 publication Critical patent/DK3402515T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17738918.6T 2016-01-12 2017-01-12 Forbedrede fremgangsmåder til monitorering af et individs immunstatus DK3402515T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277801P 2016-01-12 2016-01-12
US201662300708P 2016-02-26 2016-02-26
PCT/US2017/013169 WO2017123741A1 (en) 2016-01-12 2017-01-12 Improved methods for monitoring immune status of a subject

Publications (1)

Publication Number Publication Date
DK3402515T3 true DK3402515T3 (da) 2021-11-15

Family

ID=59312140

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17738918.6T DK3402515T3 (da) 2016-01-12 2017-01-12 Forbedrede fremgangsmåder til monitorering af et individs immunstatus

Country Status (7)

Country Link
US (1) US11698369B2 (da)
EP (2) EP3402515B8 (da)
JP (2) JP7011600B2 (da)
CA (1) CA3010019A1 (da)
DK (1) DK3402515T3 (da)
ES (1) ES2898329T3 (da)
WO (1) WO2017123741A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10126301B2 (en) 2013-02-08 2018-11-13 Institute For Myeloma & Bone Cancer Research Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
MA53732A (fr) * 2018-09-28 2022-01-05 Amgen Inc Anticorps dirigés contre bcma soluble
CN118206620A (zh) * 2022-12-09 2024-06-18 上海细胞治疗集团股份有限公司 一种多肽标签及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE69733694T2 (de) 1996-07-10 2006-07-06 Muramatsu, Takashi, Nagoya Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
GB9704444D0 (en) 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
CA2439410C (en) 2001-02-27 2011-09-06 William D. Figg Analogs of thalidomide as potential angiogenesis inhibitors
WO2003022877A1 (en) 2001-09-06 2003-03-20 Biogen Idec Ma Inc. Crystal structure of baff, and use thereof in drug design
CA2523776A1 (en) 2003-03-07 2004-09-23 Xencor, Inc. Baff mutants with at least one amino acid substitution and methods of their production
WO2006025345A1 (ja) 2004-08-31 2006-03-09 Kowa Company, Ltd. 抗ヒトbaff抗体
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
EP1836224A1 (en) 2004-12-23 2007-09-26 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
US8202698B2 (en) 2005-11-08 2012-06-19 Biogen Idec Ma Inc. Methods of evaluating BAFF
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
EP2198863A1 (en) 2006-02-27 2010-06-23 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
DK2016102T3 (da) 2006-05-03 2012-07-02 Us Gov Health & Human Serv Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
NZ594985A (en) 2009-03-10 2013-07-26 Biogen Idec Inc Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
FI3415531T3 (fi) 2011-05-27 2023-09-07 Glaxo Group Ltd Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
US10189906B2 (en) 2012-11-01 2019-01-29 Max-Delrück-Centrum Für Molekulare Medizin Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
US10126301B2 (en) 2013-02-08 2018-11-13 Institute For Myeloma & Bone Cancer Research Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
AU2015206194A1 (en) 2014-01-20 2016-07-28 Gilead Sciences, Inc. Therapies for treating cancers
JP6755805B2 (ja) 2014-04-30 2020-09-16 マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ−ゲマインシャフト Cd269(bcma)に対するヒト化抗体
US10363260B2 (en) 2014-05-28 2019-07-30 Oncotracker, Inc. Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
WO2015191668A1 (en) 2014-06-10 2015-12-17 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
HUE059131T2 (hu) 2014-08-11 2022-10-28 Acerta Pharma Bv BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
EP3227432B1 (en) 2014-12-05 2023-10-11 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
US11060150B2 (en) 2015-03-17 2021-07-13 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating cancer
MX2018000999A (es) 2015-07-24 2018-11-09 Oncotracker Inc Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico.
CN108350076B (zh) 2015-08-17 2022-06-07 詹森药业有限公司 抗-bcma抗体,结合bcma和cd3的双特异性抗原结合分子及其用途
RU2018119706A (ru) * 2015-10-30 2019-12-02 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способ прогноза
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
WO2017201040A1 (en) 2016-05-16 2017-11-23 Berenson James Richard Improved methods for monitoring immune status of a subject
MX2019001469A (es) 2016-08-01 2019-10-02 Novartis Ag Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
WO2018085363A2 (en) 2016-11-02 2018-05-11 Berenson James Richard Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
EP3654986A2 (en) 2017-07-19 2020-05-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US20220000872A1 (en) 2018-10-31 2022-01-06 Oncotracker, Inc. Method of enhancing immune-based therapy

Also Published As

Publication number Publication date
WO2017123741A1 (en) 2017-07-20
JP2019508714A (ja) 2019-03-28
EP3402515B1 (en) 2021-08-11
JP7011600B2 (ja) 2022-01-26
EP3402515B8 (en) 2021-12-08
CA3010019A1 (en) 2017-07-20
EP3402515A4 (en) 2019-07-10
US20190049437A1 (en) 2019-02-14
ES2898329T3 (es) 2022-03-07
EP3402515A1 (en) 2018-11-21
EP4079320A1 (en) 2022-10-26
JP2022058619A (ja) 2022-04-12
US11698369B2 (en) 2023-07-11

Similar Documents

Publication Publication Date Title
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3481838T3 (da) Nye fremgangsmåder til fremstillingen af oligonukleotider
DK3300500T3 (da) Triazolagonister af apj-receptoren
DK3371619T3 (da) Detektering af et ubemandet luftfartøj
DK3940352T3 (da) Fremgangsmåde til diagnosticering af vægte
DK3126373T3 (da) Fremgangsmåde til fremstilling af amg 416
DK3461891T3 (da) Nedstrømsbehandling af en alkalisk phosphatase
DK3372585T3 (da) Fremgangsmåde til fremstillingen af en diarylthiohydantoinforbindelse
DK3365563T3 (da) Forbindelseskomponent
DK3507408T3 (da) Fremgangsmåde til fremstilling af nonwoven
DE112016004797T8 (de) Zentrifugalkompressor
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3001700T3 (da) Positioneret høresystem
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3191498T3 (da) Fremgangsmåde til fremstilling af 2'-o-fucosyllactose
DK3166611T3 (da) Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer
DK3438103T3 (da) Griseofulvinforbindelse
DK3402515T3 (da) Forbedrede fremgangsmåder til monitorering af et individs immunstatus
DK3273262T3 (da) Sekundær monoimpuls-overvågningsradar
DK3120153T3 (da) Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid
DK3551629T3 (da) Oxabicycloheptaner til modulering af immunrespons